What is the treatment for a patient with a positive Rapid Plasma Reagin (RPR) test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Treatment for a positive Rapid Plasma Reagin (RPR) test involves penicillin G as the first-line therapy, with the specific regimen depending on the stage of syphilis. For primary, secondary, or early latent syphilis (less than one year), a single intramuscular injection of benzathine penicillin G 2.4 million units is recommended 1. For late latent syphilis (more than one year) or syphilis of unknown duration, three weekly doses of benzathine penicillin G 2.4 million units are needed. Neurosyphilis requires a more intensive approach with aqueous crystalline penicillin G 18-24 million units daily, administered as 3-4 million units IV every 4 hours for 10-14 days.

Key Considerations

  • For penicillin-allergic patients, doxycycline 100 mg orally twice daily for 14 days (early syphilis) or 28 days (late syphilis) is an alternative, though desensitization to penicillin is preferred for pregnant women 1.
  • Follow-up RPR testing is essential at 6,12, and 24 months to confirm treatment success, indicated by a fourfold decrease in titer.
  • Sexual partners from the past 90 days should be notified, tested, and treated presumptively.
  • Penicillin remains highly effective against Treponema pallidum because the spirochete has not developed resistance, and its long-acting formulation maintains therapeutic levels needed to eliminate the slowly dividing organism.

Special Populations

  • Pregnant women should be screened serologically for syphilis early in pregnancy, and those with reactive treponemal screening tests should have confirmatory testing with nontreponemal tests with titers 1.
  • In populations with high prevalence of syphilis or for patients at high risk, serologic testing should be performed twice during the third trimester and at delivery.

From the FDA Drug Label

Syphilis (neurosyphilis) 12 to 24 million units/day, as 2-4 MU every 4 hours for 10-14 days; many experts recommend additional therapy with Benzathine PCN G 2. 4 MU IM weekly for 3 doses after completion of IV therapy

  • The treatment for a patient with a positive Rapid Plasma Reagin (RPR) test is penicillin G (IM).
  • The recommended dosage for syphilis (neurosyphilis) is 12 to 24 million units/day, administered as 2-4 MU every 4 hours for 10-14 days.
  • Additional therapy with Benzathine PCN G 2.4 MU IM may be recommended weekly for 3 doses after completion of IV therapy 2.

From the Research

Treatment for Positive RPR

The treatment for a patient with a positive Rapid Plasma Reagin (RPR) test, which is indicative of syphilis, depends on the stage of the disease and the patient's overall health.

  • Benzathine penicillin G is the recommended treatment for early syphilis in non-penicillin-allergic patients 3, 4, 5, 6.
  • For patients who are allergic to penicillin, doxycycline or tetracycline can be used as alternative treatments 4, 5, 6.
  • The dosage and duration of treatment may vary depending on the stage of the disease and the patient's response to treatment.

Treatment Options

  • Benzathine penicillin G: 2.4 million units given intramuscularly weekly for two weeks for a total of 4.8 million units 6.
  • Doxycycline: 100 mg orally, twice daily for 14 days 4, 5.
  • Tetracycline: 500 mg orally, four times daily for 12-14 days 5, 6.
  • Azithromycin: 2.0 g orally, as a single dose or as two doses 1 week apart 3.

Special Considerations

  • HIV-positive patients may have poorer serologic responses to treatment with benzathine penicillin G compared to HIV-negative patients 7.
  • Patients with high RPR titers before treatment may become seronegative less rapidly than patients with low pretreatment titers 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.